Summary
The Adalimumab Trial Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis (AS) or ATLAS trial was a double-blind, phase III, placebo-controlled study to evaluate the ability of adalimumab to reduce signs and symptoms of AS over a one-year period.
- inflammatory disorders clinical trials
- © 2006 MD Conference Express
Tools
The ATLAS Trial: Long-Term Adalimumab Treatment Reduces Signs and Symptoms in Ankylosing Spondylitis Patients
Permalink:
Table of contents
Cited By...
- No citing articles found.